1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Denali Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company on July 27, 2026, receiving gross proceeds of $195.0 million at closing. The voucher was received when the FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026, and the sale was made under an asset purchase agreement dated June 12, 2026.
Gross proceeds of $195.0 million received from the buyer at closing on July 27, 2026
Voucher received when FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome (MPS II) in March 2026
Sale made under asset purchase agreement dated June 12, 2026; buyer not named in the filing
Full agreement to be filed as an exhibit to a later SEC filing
Centene reported second-quarter 2026 results that moved from a loss a year earlier to a profit, and raised the floor of its full-year 2026 earnings guidance. The company said the increase includes about $0.50 of non-recurring items in its Medicare and Commercial segments. A director also resigned and was replaced by Paul Diaz effective July 28, 2026, and the filing states the resignation was not due to any dispute with the company.
GAAP diluted EPS was $2.19 for Q2 2026, versus a loss of $0.51 in Q2 2025; adjusted diluted EPS was $2.51, versus a loss of $0.16
Premium and service revenues rose 4% to $44.4 billion; total revenues were $53,579 million
2026 GAAP diluted EPS guidance floor raised to greater than $3.11; adjusted diluted EPS floor raised to greater than $4.80
Director Kenneth Burdick resigned effective July 28, 2026; Paul Diaz was elected to fill the vacancy and joins the Audit and Quality and Compliance Committees
Polaris reported second quarter 2026 sales of $2,023 million, up 9% from a year earlier, and diluted EPS of $1.82 versus a loss of $1.39 per share in the prior-year quarter. The company raised its 2026 adjusted EPS guidance to $3.00 to $3.10 from $1.60 to $1.70, of which about $0.96 comes from tariff refunds recorded in the second quarter, so shareholders should weigh that one-time benefit against the higher outlook.
Q2 2026 sales were $2,023 million, up 9%; North America sales rose 11% to $1,755 million.
Reported diluted EPS was $1.82 versus a $1.39 loss a year earlier; adjusted diluted EPS was $1.97 versus $0.40.
Q2 results include $74 million of tariff refunds, which benefited adjusted EPS by $0.96.
2026 adjusted EPS guidance rose to $3.00 to $3.10 from $1.60 to $1.70; adjusted sales guidance rose to $7.30 billion to $7.50 billion from $7.15 billion to $7.30 billion.
Farmers & Merchants Bancorp reported second-quarter 2026 net income of $11.8 million, or $0.86 per share, up from $7.7 million, or $0.56 per share, a year earlier. The company said the second quarter was its most profitable quarter in its 129-year history, driven by a higher net interest margin and lower funding costs. For shareholders, the results show higher earnings per share and a 4.0% increase in the annualized dividend to $0.92 per share.
Q2 2026 net income $11.8 million ($0.86 per share) versus $7.7 million ($0.56 per share) in Q2 2025
Net interest margin rose 26 basis points to 3.48%; cost of interest-bearing liabilities fell to 2.56% from 2.83%
Total deposits of $2.87 billion at June 30, 2026, up 5.9%, or $159.1 million, from a year earlier
Annualized second-quarter dividend increased 4.0% to $0.92 per share
Nucor reported second-quarter 2026 net earnings attributable to stockholders of $1.16 billion, or $5.04 per diluted share, up from $603 million, or $2.60 per share, a year earlier and $743 million in the first quarter of 2026. Excluding a non-cash, pre-tax benefit of $61 million tied to its Helion investment, adjusted earnings were $4.84 per diluted share, and the company expects higher consolidated earnings in the third quarter of 2026.
Net sales were $10.40 billion, up from $8.46 billion in the second quarter of 2025.
Adjusted net earnings were $1.11 billion, or $4.84 per diluted share, excluding a $61 million pre-tax benefit ($0.20 per diluted share).
Nucor returned about $479 million to stockholders in the quarter through share repurchases and dividends.
An earnings call is scheduled for July 28, 2026 at 10:00 a.m. Eastern Time.
21Shares US LLC, sponsor of the 21Shares Solana ETF (TSOL), agreed on July 27, 2026 to voluntarily waive the sponsor fee it receives from the trust for one year, from July 28, 2026 through July 27, 2027. The press release says the fee falls from 0.21% to 0.00% for that period, which lowers the cost of holding the trust for shareholders during the waiver.
Sponsor fee reduced from 0.21% to 0.00%, effective July 28, 2026
Waiver is voluntary and runs through July 27, 2027
Press release announcing the waiver issued July 27, 2026 (Exhibit 99.1)
Press release cites an estimated net staking yield of about 4.29% as of July 20, 2026, which the filing says is not a measure of overall trust performance
NBT Bancorp reported second quarter 2026 net income of $53.0 million, or $1.02 per diluted share, up from $22.5 million, or $0.44, a year earlier and $51.1 million, or $0.98, in the first quarter of 2026. The board approved a third-quarter cash dividend of $0.40 per share, an 8.1% increase over the third-quarter 2025 dividend. The year-over-year comparison is significantly affected by the Evans Bancorp acquisition completed May 2, 2025, and by $17.2 million of acquisition expenses recorded in the second quarter of 2025.
Operating diluted EPS, a non-GAAP measure, was $1.01 for Q2 2026, compared with $0.88 in Q2 2025 and $0.97 in Q1 2026.
Net interest margin on an FTE basis was 3.73%, up 14 basis points from Q2 2025.
Period end loans were $11.87 billion at June 30, 2026, up from $11.60 billion at December 31, 2025.
The $0.40 dividend is payable September 15, 2026 to stockholders of record as of September 1, 2026.
Universal Health Realty Income Trust reported second-quarter 2026 net income of $5.9 million, or $0.43 per diluted share, up from $4.5 million, or $0.32, a year earlier. The result included a $724,000 gain on a land sale; excluding it, adjusted net income was $5.2 million, or $0.37 per share, and funds from operations rose to $12.5 million, or $0.90 per share, from $11.8 million, or $0.85.
Net income of $5.9 million, or $0.43 per diluted share, versus $4.5 million, or $0.32, in Q2 2025
Adjusted net income of $5.2 million, or $0.37 per diluted share, excluding a $724,000 gain on a land sale
Funds from operations of $12.5 million, or $0.90 per diluted share, versus $11.8 million, or $0.85, in Q2 2025
Second-quarter dividend of $0.75 per share, or $10.4 million in total, paid June 30, 2026
COPT Defense Properties reported higher second-quarter 2026 results for the period ended June 30, 2026. Net income was $48.6 million, up from $40.2 million a year earlier, and diluted EPS was $0.40 versus $0.34, while diluted FFO per share rose to $0.71 from $0.68. The earnings release and supplemental package were furnished as Exhibit 99.1 and were not filed under Section 18 of the Exchange Act.
Total revenues for the three months ended June 30, 2026 were $197.4 million, compared with $189.9 million a year earlier.
Diluted EPS was $0.40 for the quarter, compared with $0.34 for the same quarter of 2025.
Diluted FFO per share was $0.71 versus $0.68, and the quarterly dividend per common share was $0.32, compared with $0.305.
Simpson Manufacturing reported second-quarter 2026 net sales of $671.1 million, up 6.3%, and diluted earnings per share of $3.09, up from $2.47 a year earlier. The company also raised its 2026 share repurchase authorization to $200.0 million and updated its full-year 2026 outlook, which for shareholders means higher reported profit and more capacity for buybacks.
Net sales of $671.1 million rose 6.3%, with North America up 6.0% and Europe up 7.6%.
Income from operations of $169.1 million rose 20.6%; operating margin was 25.2%, including a 100 basis point benefit from a $5.5 million eminent domain settlement.
On July 23, 2026, the Board raised the 2026 share repurchase authorization from $150.0 million to $200.0 million; the company repurchased $48.7 million of stock in the quarter.
Updated 2026 outlook: consolidated operating margin of 19.7% to 20.5% and capital expenditures of $80.0 million to $90.0 million. The filing does not state the prior outlook.
Element Solutions reported second-quarter 2026 net sales of $978 million, up 56% on a reported basis and 15% organically, with GAAP net income of $77 million, or $0.32 per diluted share, versus $48 million, or $0.20, a year earlier. The company raised its full-year 2026 adjusted EBITDA guidance to $690 million to $710 million, but the results come alongside a July 6, 2026 merger agreement under which Solstice would acquire the company for 0.5 Solstice shares and $10.00 in cash per share.
Q2 2026 adjusted EBITDA was $184 million, up 35% on a reported basis, with adjusted EBITDA margin of 27.8% versus 26.6% a year earlier.
Full-year 2026 adjusted EBITDA guidance is $690 million to $710 million, and third-quarter adjusted EBITDA is expected to be about $180 million.
Under the July 6, 2026 merger agreement, each share would be exchanged for 0.5 shares of Solstice common stock and $10.00 in cash; closing is expected in the first half of 2027.
Park National Corporation reported second-quarter 2026 net income of $58.8 million, up 22.1% from a year earlier, and diluted earnings of $3.23 per share versus $2.97. The results include $4.1 million in merger-related expenses tied to the First Citizens acquisition, which merged into Park on February 1, 2026. The board declared a $1.10 quarterly dividend payable September 10, 2026.
Q2 2026 net income of $58.8 million, up 22.1% from $48.1 million in Q2 2025
Q2 2026 diluted EPS of $3.23, compared with $2.97 in Q2 2025
First-half 2026 net income of $100.4 million, up 11.3%; diluted EPS of $5.64 versus $5.56
Quarterly dividend of $1.10 per share, payable September 10, 2026, to holders of record as of August 21, 2026
Happen, Inc. (Nasdaq: HAPN), parent of Happen Bank, reported second quarter 2026 results with total net revenue of $262.9 million, up 6% from a year earlier, and net income of $58.1 million, up 52%. The company also gave third quarter and full-year 2026 outlooks, with full-year diluted EPS guided to $1.80 to $1.90.
Diluted EPS was $0.50 for the quarter, compared with $0.33 a year earlier and $0.44 in the first quarter of 2026.
Pre-tax income was $75.7 million, which the company describes as a record, and the pre-tax profit margin was 28.8%, compared with 21.7% a year earlier.
Third quarter 2026 guidance calls for diluted EPS of $0.43 to $0.48 and loan originations of $3.20 billion to $3.35 billion.
Full-year 2026 guidance calls for diluted EPS of $1.80 to $1.90 and loan originations of $12.2 billion to $12.6 billion.
Slide Insurance Holdings declared its initial quarterly cash dividend of $0.07 per share, payable August 28, 2026, to holders of record as of August 14, 2026. The filing says the dividend reflects management's confidence in the business and balance sheet, and that future dividends remain at the Board's discretion.
Initial quarterly dividend of $0.07 per common share
Payable August 28, 2026 to shareholders of record as of August 14, 2026
Future dividends subject to Board discretion and financial condition and results of operations
Filing contains no financial results, earnings or guidance figures
Commercial Bancgroup, Inc. (Nasdaq: CBK) reported second-quarter 2026 net income of $10.2 million, or $0.75 per basic share, up from $8.9 million, or $0.73 per share, a year earlier. The company also declared a quarterly cash dividend of $0.12 per share, payable September 30, 2026, to holders of record on September 15, 2026. Net interest margin rose to 4.06% from 3.88% in the first quarter, and book value per share increased to $22.09.
Q2 2026 net income of $10.2 million, or $0.75 basic and $0.74 diluted per share, versus $8.9 million, or $0.73 per share, in Q2 2025.
Net interest margin of 4.06%, up 18 basis points from the first quarter of 2026.
Quarterly cash dividend of $0.12 per share, payable September 30, 2026, to shareholders of record on September 15, 2026.
Six-month net income of $19.8 million, or $1.44 per share, compared with $17.6 million, or $1.44 per share, a year earlier.
Principal Financial Group reported second quarter 2026 results, with non-GAAP operating earnings per diluted share up 16% to $2.50 and GAAP net income attributable to PFG slightly lower at $403.4 million. The company also announced a third quarter dividend of $0.84 per share, up $0.02 from the prior quarter and 8% above the prior year quarter, which gives shareholders a higher cash payout.
Non-GAAP operating earnings per diluted share were $2.50, up from $2.16 a year earlier; excluding significant variances, it was $2.42, up 17%.
GAAP net income attributable to PFG was $403.4 million, down 1% from $406.2 million, while GAAP diluted EPS rose 3% to $1.84.
The company returned $427 million to shareholders in the quarter, including $250 million of share repurchases and $177 million of common stock dividends.
The third quarter dividend of $0.84 per share is payable September 25, 2026, to holders of record as of September 3, 2026.
Amkor Technology reported second-quarter 2026 net sales of $1.90 billion, up 26% from a year earlier, with net income attributable to Amkor of $174 million and diluted earnings of $0.70 per share. The company also guided third-quarter 2026 net sales of $1.95 billion to $2.05 billion and diluted EPS of $0.72 to $0.82, and kept its quarterly dividend subject to board approval. Q2 2025 results included a $32 million contingency benefit tied to the 2017 Nanium acquisition, so the year-over-year comparison is not fully like-for-like.
Q2 2026 net sales $1.90 billion vs. $1.51 billion in Q2 2025; gross margin 16.8% vs. 12.0%
Net income attributable to Amkor $174 million; diluted EPS $0.70 vs. $0.22 in Q2 2025
Q3 2026 guidance: net sales $1.95 billion to $2.05 billion; diluted EPS $0.72 to $0.82
At June 30, 2026: cash and short-term investments $2.5 billion; total debt $2.5 billion
F5 reported fiscal third-quarter 2026 revenue of $865 million, up 11% from $780 million a year earlier, and GAAP diluted earnings of $3.62 per share versus $3.25. The company raised its fiscal 2026 revenue growth and non-GAAP earnings per share guidance, which gives shareholders a higher expected range for the full year.
Third-quarter revenue was $865 million, up 11%; product revenue grew 19% and systems revenue grew 32%.
GAAP diluted EPS was $3.62 versus $3.25; non-GAAP diluted EPS was $4.73 versus $4.16.
Fiscal 2026 revenue growth guidance was raised to 9% to 10% from 7% to 8%.
Fiscal 2026 non-GAAP EPS guidance was raised to $17.21 to $17.33 from $16.25 to $16.55; fourth-quarter revenue is guided to $870 million to $890 million.
Rambus reported second-quarter 2026 results, with total revenue of $207.4 million, up from $172.2 million a year earlier, and GAAP diluted earnings per share of $0.61, up from $0.53. The company also gave third-quarter 2026 guidance of $210 million to $216 million in revenue and GAAP diluted earnings per share of $0.59 to $0.67. For shareholders, the filing shows higher revenue and profit year over year, along with a forecast for continued revenue growth in the third quarter.
Q2 2026 total revenue was $207.4 million, above the company's guidance range of $192 million to $198 million
GAAP diluted EPS was $0.61 versus $0.53 a year earlier; non-GAAP diluted EPS was $0.77 versus $0.62
Product revenue was $99.2 million, up from $81.3 million; operating margin was 35% versus 37% a year earlier
Q3 2026 guidance: revenue of $210 million to $216 million and GAAP diluted EPS of $0.59 to $0.67
Northwest Bancshares reported record second-quarter 2026 GAAP net income of $54 million, or $0.36 per diluted share, up from $34 million, or $0.26, a year earlier and $51 million, or $0.34, in the first quarter of 2026. Growth was supported by higher net interest income and a net interest margin of 3.75%, with the Penns Woods acquisition cited as a key driver of higher loans, deposits and expenses. The board also declared a quarterly cash dividend of $0.20 per share.
GAAP net income of $54 million, or $0.36 per diluted share, versus $34 million, or $0.26, in Q2 2025; adjusted diluted EPS (non-GAAP) was $0.37.
Net interest margin rose to 3.75% from 3.56% a year earlier; net interest income was $147 million, up 23.0% year over year.
Classified loans were $524 million, or 3.96% of total loans, at June 30, 2026, compared with $498 million at March 31, 2026.
Quarterly cash dividend of $0.20 per share, payable August 18, 2026 to holders of record on August 6, 2026.
Agilysys reported fiscal 2027 first-quarter revenue of $87.7 million, up 14.3% from $76.7 million a year earlier, and net income of $9.0 million, or $0.32 per diluted share, versus $4.9 million, or $0.17, a year earlier. The company raised its full-year fiscal 2027 total revenue guidance to $368 million to $373 million from $365 million to $370 million, which signals stronger expected sales for shareholders.
Total net revenue rose 14.3% to $87.7 million; subscription revenue grew 26.1% year over year.
Net income was $9.0 million, or $0.32 per diluted share, compared with $4.9 million, or $0.17, a year earlier.
Full-year fiscal 2027 total revenue guidance raised to $368 million to $373 million; subscription revenue growth guidance raised to at least 32% from at least 30%.
Free cash flow (non-GAAP) was $7.3 million, compared with negative $5.0 million a year earlier.
Kforce reported second-quarter 2026 revenue of $349.3 million, up 4.5% from a year earlier, and diluted EPS of $0.73, up 23.7% year over year. The company expects third-quarter revenue of $349 million to $357 million and EPS of $0.71 to $0.79, and its board approved a $0.40 per share dividend.
Q2 2026 revenue was $349.3 million, up 5.7% sequentially and 4.5% year over year.
Diluted EPS was $0.73 versus $0.59 in Q2 2025; gross profit margin was 28.5%, up 140 basis points year over year.
Q3 2026 guidance: revenue of $349 million to $357 million and EPS of $0.71 to $0.79.
Board approved a $0.40 per share third-quarter dividend, payable September 25, 2026 to holders of record on September 11, 2026.
Cadence reported second-quarter 2026 revenue of $1.584 billion, up from $1.275 billion a year earlier, and GAAP diluted EPS of $1.33 versus $0.59. The company raised its full-year 2026 revenue and non-GAAP EPS outlook and reported a record backlog of $8.1 billion, which signals higher expected revenue and earnings for shareholders.
Q2 2026 GAAP diluted EPS was $1.33 versus $0.59 in Q2 2025; non-GAAP diluted EPS was $2.11 versus $1.65.
FY 2026 revenue outlook raised to $6.26 billion to $6.34 billion; non-GAAP EPS outlook raised to $8.05 to $8.15.
Quarter-end backlog was a record $8.1 billion.
Q3 2026 revenue outlook is $1.595 billion to $1.625 billion, and the company expects to use about $200 million to repurchase shares in Q3.
Bank of Hawai‘i reported second quarter 2026 diluted earnings per share of $1.47, up from $1.30 in the prior quarter, and net income of $63.8 million, up 11.1% from the prior quarter. Net interest margin rose to 2.78%, its ninth consecutive quarterly expansion, while average total deposits were modestly lower. For shareholders, the company also repurchased $17.0 million of common stock and declared a $0.70 per share quarterly dividend.
Diluted EPS of $1.47 versus $1.30 in the linked quarter and $1.06 a year earlier
Net income of $63.8 million, up 11.1% from the linked quarter
Net interest margin of 2.78%, up 4 basis points from the linked quarter
Repurchased $17.0 million of common stock; $0.70 dividend payable September 15, 2026
The FDA approved Freenome's SimpleScreen CRC, a blood-based colorectal cancer screening test for adults 45 and older at average risk. Under an August 2025 agreement, Freenome will receive a $100 million milestone payment from Abbott, which will exclusively commercialize the test in the U.S. this fall.
FDA approved SimpleScreen CRC for adults 45 and older at average risk for colorectal cancer, announced July 27, 2026.
In the PREEMPT CRC study of more than 48,000 adults, the test showed 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia.
Freenome will receive a $100 million milestone payment from Abbott for the FDA approval; Abbott plans to commercialize the test in the U.S. this fall.
California BanCorp reported second-quarter 2026 net income of $14.3 million, or $0.44 per diluted share, up from $13.8 million, or $0.42, in the first quarter. Its board also approved a quarterly dividend of $0.12 per share, up $0.02 from the prior quarter, payable October 15, 2026. Nonperforming assets fell to 0.44% of total assets from 0.97%, which shows improved credit quality for shareholders.
Net income of $14.3 million, or $0.44 per diluted share, versus $13.8 million, or $0.42, in Q1 2026
Net interest margin of 4.71%, compared with 4.47% in the prior quarter
Nonperforming assets were 0.44% of total assets at June 30, 2026, down from 0.97% at March 31, 2026
Quarterly dividend of $0.12 per share payable October 15, 2026, to holders of record on September 21, 2026
Hope Bancorp reported second-quarter 2026 net income of $33.0 million, or $0.26 per diluted share, up 12% from the first quarter and up from a net loss of $24.8 million a year earlier. The company also declared a $0.14 quarterly dividend and said its pending acquisition of the Commercial Banking Unit of SMBC MANUBANK remains subject to regulatory approvals and other closing conditions.
Q2 2026 net income $33.0 million ($0.26 per diluted share), vs. $29.5 million ($0.23) in Q1 2026 and a net loss of $24.8 million in Q2 2025
Net income excluding notable items was $34.5 million ($0.27 per diluted share), up from $29.7 million in Q1 2026
Net interest margin rose to 2.96% from 2.90% in Q1 2026; net interest income was $129.0 million
Quarterly dividend of $0.14 per share is payable on or about August 20, 2026, to holders of record as of August 6, 2026
Alliance Resource Partners reported second-quarter 2026 revenue of $551.6 million, up 0.7% year over year, and net income attributable to ARLP of $79.6 million, or $0.61 per unit, compared with $59.4 million, or $0.46 per unit, a year earlier. The partnership also declared a $0.60 per unit quarterly distribution, completed a $206.2 million oil and gas royalty acquisition on July 1, 2026, and updated its 2026 volume guidance to include the acquired assets. For the six months, however, net income fell to $88.7 million from $133.4 million.
Q2 2026 total revenues were $551.6 million versus $547.5 million in Q2 2025; Adjusted EBITDA rose 14.7% to $185.7 million.
Net income attributable to ARLP was $79.6 million ($0.61 per unit) versus $59.4 million ($0.46 per unit) in Q2 2025.
Six-month 2026 net income was $88.7 million ($0.68 per unit), down from $133.4 million ($1.03 per unit) in the first half of 2025.
Quarterly distribution of $0.60 per unit is payable August 14, 2026 to unitholders of record on August 7, 2026.
Ponce Financial Group reported second-quarter 2026 net income available to common stockholders of $8.2 million, or $0.35 per diluted share, up from $0.25 in the same quarter of 2025 but slightly below $0.36 in the first quarter of 2026. The company also said it believes it has met the lending conditions to repurchase its Preferred Stock from the U.S. Treasury, but completion depends on additional conditions and there is no assurance of timing.
Net income available to common stockholders was $8.2 million, or $0.35 per diluted share, for the quarter ended June 30, 2026, versus $8.3 million, or $0.36, in the prior quarter and $5.8 million, or $0.25, a year earlier.
Net interest income rose 23.07% from a year earlier to $30.1 million, and net interest margin was 3.66%, versus 3.27% a year earlier.
Non-interest expense was $18.1 million, up 7.50% from $16.9 million in the second quarter of 2025.
Deposits were $2.27 billion as of June 30, 2026, up 11.00% from December 31, 2025; the company expects to satisfy other conditions for a Preferred Stock repurchase under its ECIP Purchase Option Agreement with the U.S. Treasury, but no timi
Neumora Therapeutics said a repeat 13-week rat toxicology study of NMRA-215 showed no unexpected in-life adverse findings, after an earlier study had reported such findings in 5 of 142 animals. The company continues to believe the earlier findings were not related to NMRA-215 and plans to submit an IND application in the fourth quarter of 2026.
Repeat 13-week rat toxicology study in 162 animals showed no unexpected in-life adverse findings.
A for-cause audit of the earlier study found various discrepancies and a number of critical audit observations.
The company plans to submit an IND in the fourth quarter of 2026 and initiate a Phase 1 study by the end of 2026.
MapLight Therapeutics reported topline results from ZEPHYR, a Phase 2 trial of ML-007C-MA in hospitalized adults with schizophrenia experiencing an acute exacerbation of psychosis, on July 27, 2026. The 210/3 mg twice-daily dose met the primary endpoint, reducing PANSS total score by 4.5 points more than placebo at Week 5, while the 330/6 mg once-daily arm did not reach statistical significance. The company plans to discuss next steps with the FDA at an end-of-phase 2 meeting before a further pivotal trial.
210/3 mg BID arm: PANSS total score down 4.5 points versus placebo at Week 5 (p=0.015), meeting the primary endpoint
330/6 mg QD arm: 2.8 points versus placebo, p=0.110, not statistically significant
Prespecified cognitive composite score improved in the baseline-impaired subgroup (effect size 0.51, p=0.041)
Company plans to engage the FDA at an end-of-phase 2 meeting and identify sites for an additional pivotal trial
Lakeland Financial Corporation reported record second-quarter 2026 net income of $28.4 million, up 5% from $27.0 million a year earlier, with diluted earnings per share of $1.13 versus $1.04. Total revenue rose 7% to $70.9 million, and average loans grew 6%, which supports the company's earnings growth for shareholders.
Q2 2026 net income was $28.4 million, up $1.5 million, or 5%, from $27.0 million in Q2 2025.
Diluted EPS was $1.13, up $0.09, or 9%, from $1.04; first-half 2026 diluted EPS was $2.17, up 19%.
Total revenue was $70.9 million, up 7% year over year; net interest margin was 3.49%, up 7 basis points.
Quarterly common dividend rose to $0.52 per share from $0.50, payable August 5, 2026; the company repurchased 70,873 shares at $58.20 on average.
The Ensign Group reported second-quarter 2026 GAAP diluted earnings of $1.68 per share, up from $1.44 a year earlier, and adjusted earnings of $1.92 per share, up from $1.59. It raised its 2026 earnings guidance to $7.75 to $7.85 per diluted share from $7.48 to $7.62, and its revenue guidance to $5.87 billion to $5.92 billion from $5.81 billion to $5.86 billion, which matters to shareholders because it signals stronger expected profit and sales for the full year.
Q2 2026 GAAP diluted EPS was $1.68, versus $1.44 in Q2 2025; net income attributable to the company was $99.7 million
Consolidated revenue was $1.44 billion for the quarter, up 17.3% from the prior year quarter
2026 diluted EPS guidance raised to $7.75 to $7.85 from $7.48 to $7.62
2026 revenue guidance raised to $5.87 billion to $5.92 billion from $5.81 billion to $5.86 billion
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.